Aviva PLC Raises Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Aviva PLC raised its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 17.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,105 shares of the medical equipment provider’s stock after buying an additional 1,037 shares during the quarter. Aviva PLC’s holdings in Lantheus were worth $636,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of LNTH. Dynamic Technology Lab Private Ltd bought a new position in shares of Lantheus in the fourth quarter worth $459,000. Resona Asset Management Co. Ltd. purchased a new position in Lantheus during the fourth quarter worth about $440,000. Riverwater Partners LLC increased its stake in Lantheus by 102.9% in the 4th quarter. Riverwater Partners LLC now owns 11,182 shares of the medical equipment provider’s stock worth $1,000,000 after acquiring an additional 5,671 shares during the last quarter. Landscape Capital Management L.L.C. raised its holdings in shares of Lantheus by 312.8% in the 4th quarter. Landscape Capital Management L.L.C. now owns 16,358 shares of the medical equipment provider’s stock valued at $1,463,000 after acquiring an additional 12,395 shares in the last quarter. Finally, Foundry Partners LLC boosted its position in shares of Lantheus by 4.5% during the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider’s stock valued at $278,000 after acquiring an additional 133 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Performance

Shares of LNTH opened at $98.51 on Friday. Lantheus Holdings, Inc. has a fifty-two week low of $59.56 and a fifty-two week high of $126.89. The firm has a 50 day moving average price of $93.80 and a 200-day moving average price of $95.67. The firm has a market cap of $6.75 billion, a price-to-earnings ratio of 16.39 and a beta of 0.20.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. As a group, equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Wall Street Analyst Weigh In

LNTH has been the topic of several research analyst reports. The Goldman Sachs Group began coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective on the stock. JMP Securities reissued a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial lifted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. Finally, B. Riley cut their target price on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research report on Friday, March 21st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $129.43.

Insider Activity at Lantheus

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 64,109 shares of company stock worth $6,110,806 in the last ninety days. 1.50% of the stock is owned by company insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.